Nevertheless, using publically available single-cell data, we find that CD73 is mainly expressed by cancer cells in human PDAC tumors, indicating that CD73-blocking therapy could target aggressive cancer cells with less effects on other cell populations within tumor microenvironment. Here, NT5E is linked to cancer.